170 related articles for article (PubMed ID: 19739071)
1. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study).
Rijkaart DC; Berkhof J; van Kemenade FJ; Rozendaal L; Verheijen RH; Bulk S; Herreilers ME; Verweij WM; Snijders PJ; Meijer CJ
Int J Cancer; 2010 May; 126(9):2175-81. PubMed ID: 19739071
[TBL] [Abstract][Full Text] [Related]
2. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
[TBL] [Abstract][Full Text] [Related]
3. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
Bulkmans NW; Rozendaal L; Snijders PJ; Voorhorst FJ; Boeke AJ; Zandwijken GR; van Kemenade FJ; Verheijen RH; v Groningen K; Boon ME; Keuning HJ; van Ballegooijen M; van den Brule AJ; Meijer CJ
Int J Cancer; 2004 May; 110(1):94-101. PubMed ID: 15054873
[TBL] [Abstract][Full Text] [Related]
4. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.
Kelly RS; Patnick J; Kitchener HC; Moss SM;
Br J Cancer; 2011 Sep; 105(7):983-8. PubMed ID: 21897395
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.
Rijkaart DC; Coupe VM; van Kemenade FJ; Heideman DA; Hesselink AT; Verweij W; Rozendaal L; Verheijen RH; Snijders PJ; Berkhof J; Meijer CJ
Br J Cancer; 2010 Sep; 103(7):939-46. PubMed ID: 20808310
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.
Berkhof J; de Bruijne MC; Zielinski GD; Bulkmans NW; Rozendaal L; Snijders PJ; Verheijen RH; Meijer CJ
Int J Cancer; 2006 Apr; 118(7):1759-68. PubMed ID: 16217759
[TBL] [Abstract][Full Text] [Related]
11. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.
Gök M; van Kemenade FJ; Heideman DA; Berkhof J; Rozendaal L; Spruyt JW; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Mar; 130(5):1128-35. PubMed ID: 21484793
[TBL] [Abstract][Full Text] [Related]
12. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
13. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.
Verhoef VM; Bosgraaf RP; van Kemenade FJ; Rozendaal L; Heideman DA; Hesselink AT; Bekkers RL; Steenbergen RD; Massuger LF; Melchers WJ; Bulten J; Overbeek LI; Berkhof J; Snijders PJ; Meijer CJ
Lancet Oncol; 2014 Mar; 15(3):315-22. PubMed ID: 24529697
[TBL] [Abstract][Full Text] [Related]
14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
15. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
17. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
[TBL] [Abstract][Full Text] [Related]
19. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
20. Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.
Kocken M; Berkhof J; van Kemenade FJ; Louwers JA; Zaal A; Nobbenhuis MA; Kenter G; Snijders PJ; Meijer CJ; Helmerhorst TJ
Br J Cancer; 2012 Feb; 106(5):817-25. PubMed ID: 22333596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
